hotspot -WSS

hotspot

author：Wikipedia 2025-08-12 09:09:30 - browse：18192

Adam's take main illustration — Molly Ferguson/STAT

The approval Friday of Bluebird Bio’s gene therapy for sickle cell disease should have been a momentum-swinging achievement for the long-struggling biotech. Instead, the company mispriced its new drug and fumbled a pivotal financial lifeline.

The consequences of these strategic blunders — arguably, self-inflicted — could imperil Bluebird’s independence, perhaps even its survival.

Bluebird priced Lyfgenia at $3.1 million, while Vertex Pharmaceutical set the cost of Casgevy, its competing sickle cell treatment also approved on Friday, at $2.2 million. Not only is Lyfgenia significantly more expensive, but its prescribing label carries a “black box” safety warning, which requires patients undergo regular blood monitoring for cancer risk. Casgevy has no similar monitoring requirement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： FDA greenlights medical device to combat bladder issues

WSS

CDC launches VaccineFinder tool to locate Covid

Zapping the brain for stroke rehab: Pivotal clinical trial begins

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

Sage's campaign to raise awareness of postpartum depression hits a nerve

Listen: Vivek Ramaswamy's star turn & leaky drug data

FDA greenlights medical device to combat bladder issues

focus

hotspot

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

Former Georgia lieutenant governor says he received grand jury subpoena

Tori Bowie and the unacceptable rates of Black maternal death

How to make over

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

FDA greenlights medical device to combat bladder issues

Alkermes shareholders re

Wegovy cuts risk of cardiovascular events by 20%, study finds

Bright Health sells Medicare Advantage business to Molina

Intellia plays down concerns on accidental germline transmission

knowledge

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

Hospitals use virtual reality to design more inclusive rooms for kids

Germany receives 178 compensation applications from gay servicepeople over discrimination

Kellogg’s is going to war over Mexico’s nutrition label rules

Hospitals use virtual reality to design more inclusive rooms for kids

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

focus

Wikipedia

focus

entertainment